TherapeuticsMD, Inc. operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands. It markets its products primarily through a direct national sales force to health care providers in the OB/GYN market space. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TXMD
Previous SymbolNYSEMKT:TXMD
CUSIPN/A
Phone561-961-1900
Debt
Debt-to-Equity Ratio0.55
Current Ratio7.23
Quick Ratio7.15
Price-To-Earnings
Trailing P/E Ratio-13.22
Forward P/E Ratio-7.89
P/E GrowthN/A
Sales & Book Value
Annual Sales$16.78 million
Price / Sales69.32
Cash FlowN/A
Price / CashN/A
Book Value$0.56 per share
Price / Book8.73
Profitability
EPS (Most Recent Fiscal Year)($0.37)
Net Income$-76,920,000.00
Net Margins-757.59%
Return on Equity-102.15%
Return on Assets-67.96%
Miscellaneous
Employees173
Outstanding Shares237,880,000
Market Cap$1.12 billion
OptionableOptionable
TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions
What is TherapeuticsMD's stock symbol?
TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."
How were TherapeuticsMD's earnings last quarter?
TherapeuticsMD Inc (NASDAQ:TXMD) posted its quarterly earnings results on Wednesday, November, 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.22) by $0.06. The firm had revenue of $3.47 million for the quarter, compared to analyst estimates of $4.43 million. TherapeuticsMD had a negative net margin of 757.59% and a negative return on equity of 102.15%. The company's quarterly revenue was down 21.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.07) earnings per share. View TherapeuticsMD's Earnings History.
When is TherapeuticsMD's next earnings date?
What price target have analysts set for TXMD?
5 Wall Street analysts have issued twelve-month price objectives for TherapeuticsMD's shares. Their predictions range from $9.00 to $27.00. On average, they anticipate TherapeuticsMD's share price to reach $15.25 in the next year. This suggests a possible upside of 211.9% from the stock's current price. View Analyst Price Targets for TherapeuticsMD.
What is the consensus analysts' recommendation for TherapeuticsMD?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TherapeuticsMD.
Has TherapeuticsMD been receiving favorable news coverage?
Media headlines about TXMD stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. TherapeuticsMD earned a news impact score of 1.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the immediate future.
Are investors shorting TherapeuticsMD?
TherapeuticsMD saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 69,651,906 shares, an increase of 4.4% from the October 15th total of 66,719,902 shares. Based on an average trading volume of 3,686,691 shares, the days-to-cover ratio is presently 18.9 days. Currently, 36.5% of the company's stock are sold short. View TherapeuticsMD's Current Options Chain.
Who are some of TherapeuticsMD's key competitors?
Some companies that are related to TherapeuticsMD include HUTCHISON CHINA/S (HCM), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO), Agios Pharmaceuticals (AGIO), Horizon Pharma (HZNP), FibroGen (FGEN), Emergent Biosolutions (EBS), Ligand Pharmaceuticals (LGND), Array Biopharma (ARRY), Evotec (EVTCY), Intercept Pharmaceuticals (ICPT), Endo International (ENDP), Madrigal Pharmaceuticals (MDGL), Mallinckrodt (MNK) and Blueprint Medicines (BPMC).
Who are TherapeuticsMD's key executives?
TherapeuticsMD's management team includes the folowing people:
- Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 47)
- Mr. John C. K. Milligan IV, Pres, Sec. & Director (Age 56)
- Dr. Brian A. Bernick, Co-Founder, Chief Clinical Officer & Director (Age 50)
- Mr. Daniel Alan Cartwright, CFO & Treasurer (Age 60)
- Mr. Mitchell L. Krassan, Exec. VP & Chief Strategy Officer (Age 52)
Who are TherapeuticsMD's major shareholders?
TherapeuticsMD's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (13.08%), BlackRock Inc. (6.94%), FMR LLC (5.21%), Franklin Resources Inc. (4.33%), First Eagle Investment Management LLC (1.20%) and Perceptive Advisors LLC (0.63%). Company insiders that own TherapeuticsMD stock include Brian Bernick, Daniel A Cartwright, John CK Iv Milligan, Robert G Finizio and Tommy G Thompson. View Institutional Ownership Trends for TherapeuticsMD.
Which institutional investors are selling TherapeuticsMD stock?
TXMD stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Franklin Resources Inc., Bank of New York Mellon Corp, Credit Suisse AG, Cornerstone Wealth Management LLC, Corrado Advisors LLC and ING Groep NV. Company insiders that have sold TherapeuticsMD company stock in the last year include Brian Bernick, Daniel A Cartwright, John CK Iv Milligan and Robert G Finizio. View Insider Buying and Selling for TherapeuticsMD.
Which institutional investors are buying TherapeuticsMD stock?
TXMD stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., Perceptive Advisors LLC, Loomis Sayles & Co. L P, First Eagle Investment Management LLC, AXA, Bamco Inc. NY and First Trust Advisors LP. View Insider Buying and Selling for TherapeuticsMD.
How do I buy shares of TherapeuticsMD?
Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TherapeuticsMD's stock price today?
One share of TXMD stock can currently be purchased for approximately $4.89.
How big of a company is TherapeuticsMD?
TherapeuticsMD has a market capitalization of $1.12 billion and generates $16.78 million in revenue each year. The company earns $-76,920,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. TherapeuticsMD employs 173 workers across the globe.
What is TherapeuticsMD's official website?
How can I contact TherapeuticsMD?
TherapeuticsMD's mailing address is 6800 BROKEN SOUND PARKWAY NW, BOCA RATON FL, 33487. The company can be reached via phone at 561-961-1900 or via email at [email protected]
MarketBeat Community Rating for TherapeuticsMD (NASDAQ TXMD)
MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe TXMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
